CLINICAL_TRIALS
trial_result
· 2013-07-11
Clinical Trial Update: Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain [Phase 3]
Summary
Phase 3 long-term safety study of Nasalfent (fentanyl citrate nasal spray) for breakthrough cancer pain has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Archimedes Development Ltd | Conditions: Cancers, Pain | Phase 3 | Status: COMPLETED